Latest report suggests that result of a strategic review will see the company’s product and IP arms separate, but current courtroom tussle with Comcast means the timing is not great
After Microsoft’s headline grabbing decision to sign-up to the network last year, LOT CEO “absolutely expects IBM to join” once its Red Hat acquisition is finalised
The Asia IP Elite identifies companies and institutions in the region that have world class IP functions. Here we introduce the 18 latest additions and explain why they have made the cut
Increased R&D outsourcing and patent licensing account for pharma’s diminishing representation among the world’s top 100 innovators, while technological diversification may also be playing its part
Delaware lawsuit is first move to litigate assets since former RPX dealmaker took control of portfolio
The Korean electronics giant has bought Corephotonics, an Israeli startup that is taking on Apple in Judge Lucy Koh’s Northern District of California courtroom
Large portfolios can often give companies a lot of sway in licensing discussions, but those numbers can be manipulated and skew the true strength of a business’s patent position.
From uncertainty over patent eligibility to the forces of convergence increasingly shaping the sector, IP strategy has never been more important for medical device companies.